Singapore, Jan. 23 -- Japan-based pharmaceutical firm Daiichi Sankyo has further established its presence in Canada with the official opening of its permanent headquarters in Toronto, including additional operational and research and development investment, underscoring the strategic importance of Canada in the growth of Daiichi Sankyo as a global leader in oncology.

"Establishing a permanent headquarters in Toronto represents a significant milestone in our global expansion and reflects the strong commitment of Daiichi Sankyo to patients and partners in Canada," said Masahiro Kato, Managing Director, Europe and Canada, Daiichi Sankyo. "Canada is home to a vibrant healthcare and life sciences ecosystem where we see immense potential for c...